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Abstract
Rigsbee, Laura Jean. M.S., Biochemistry and Molecular Biology M.S. Program,Wright State
University, 2011. Interrogation of the Distal Gut Microbiota of Healthy Adolescents and
those with Irritable Bowel Syndrome.
The human-associated microbiota has been the focus of much current research, with
the microbiota inhabiting the gastrointestinal tract of particular interest. These organisms play
many roles in human health and well-being. However, shifts in the composition of the
intestinal microbiota have been associated with diseases such as irritable bowel syndrome,
inflammatory bowel disease, and colon cancer. Several recent studies have reported on the
distal gut microbiota composition of healthy adults and those with IBS, while there is a lack
of studies devoted to adolescents. This study utilized a custom-designed Affymetrix
Microbiota Array capable of detecting 775 phylo-species of intestinal bacteria to determine
the composition of the distal gut microbiota of 22 adolescents suffering from IBS-D
(diarrhea-predominant) and 22 healthy adolescents. High sample-to-sample variation was
observed in both groups at genus level. While some differences were observed in mean
relative abundance of several bacterial genera between IBS-D and healthy adolescents,
including Bifidobacterium, Lactobacillus, Veillonella, and Prevotella, these differences were
not significant. Sample groups also failed to separate in PCA space. Therefore, we cannot
conclude that the distal gut microbiota of adolescents with IBS-D is significantly different
than that of healthy adolescents.
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1. INTRODUCTION
Introduction to the Human Intestinal Microbiota
Unique microbial communities are found in many different niches on Earth,
including communities within the soil, fresh and saltwater, on the leaves of plants, and those
associated with animals. Both vertebrates and invertebrates harbor prokaryotes which play
important roles in health and disease. Birds and mammals have high numbers of prokaryotes
associated with the skin, and especially the gastrointestinal tract (Whitman, et al., 1998).
Virtually every surface on the human body that is exposed to the outside environment is
colonized by microbes, including, but not limited to, the skin, oral cavity, respiratory tract,
esophagus, and genitourinary tract (Sekirov, et al., 2010). According to Willett et al., there
are approximately 103-104 bacterial cells/cm2 on the human skin, except in the groin and
axilla where the density increases approximately 1000-fold to 106 cells/cm2. This pales in
comparison to the vast numbers that are found throughout the gastrointestinal tract, which
contains up to 100 trillion bacterial cells, with the vast majority located within the colon.
All three domains of life, bacteria, eukarya, and archaea, can be found within the
human intestinal tract (Whitman et al., 1998). According to Ley et al., 2006, within a given
intestinal habitat, some of the microbial members function as “residents,” which would
generally be always present in fairly stable numbers within the intestinal tract, while others
act more like “hitchhikers”, resulting from ingested food, water, and the environment, and
may not always be present within the gastrointestinal tract of an individual. While the
bacterial population density in the gastrointestinal environment is among the highest known,
the diversity of the major phyla present is actually quite limited as compared to the diversity
1

found in other environments, such as the soil and ocean. The human gastrointestinal
microbiota is composed of mainly obligate anaerobes, dominated by the phylum Firmicutes,
followed by Bacteroidetes and Actinobacteria. Several other phyla can also be found in the
gastrointestinal tract, although they are much less abundant. They include Proteobacteria,
Spirochaetes, Fusobacteria, Verrucomicrobiae, and Lentisphaerae. Frank et al. examined
biopsy samples from the small intestine and colon of healthy individuals, and noted that the
small intestine samples were composed mainly of Bacilli, Streptococcaceae, Actinobacteria,
Actinomycinaceae, and Corynebacteriaceae, while colon samples were dominated by
Bacteroidetes and Lachnospiraceae. A few acid-tolerant bacterial genera were detected in the
stomach; they included Lactobacillus, Veillonella, and Helicobacter.
The colon is estimated to contain approximately 70% of all microbes associated with
the human body (Sekirov et al., 2010). According to Gebbers et al., 1989, the surface area of
the human gut is similar to that of a tennis court (200m2), which provides a very large area for
microbial colonization. The number of microbes in the human gastrointestinal tract increases
dramatically moving from the stomach, to the small intestine, and into the colon. Starting at
the stomach, there are approximately 10 bacterial cells per gram of contents, increasing to 103
cells/gram in the duodenum, 104 cells/gram in the jejunum, 107 cells/gram in the ileum, and
1012 cells/gram in the colon (Sekirov et al., 2010). Collectively, these microorganisms contain
100 times more genes than the human genome (Sartor et al., 2008). Moving from the stomach
to the colon, oxygen levels and pH change drastically, therefore; the composition and
diversity of the inhabiting microbes vary greatly between the different areas of the
gastrointestinal tract. The stomach has a pH of about 2, while the proximal small bowel
ranges from 5.5-7.0, and the distal ileum from 6.5-7.5. In the caecum, a decrease in pH is
seen, ranging from 5.5-7.5, which then rises again in the distal colon to 6.1-7.5 (Nugent et al.,
2001).
2

The human intestinal microbiota plays many roles in human health and well-being.
Among those roles are carbohydrate and fiber degradation, modulation of uptake and
deposition of dietary lipids, production of certain vitamins and short-chain fatty acids,
development and proper stimulation of the immune system, modulation of gut motility, and
protection of the host from intestinal pathogens (Sekirov et al., 2010). Germ-free animals
were observed to require higher caloric intake to maintain the same body weight as control
animals. A study by Backhed, et al., 2005, looked at germ-free versus conventionally-raised
mice. They noted that the conventionally-raised mice had 40% more body fat than the germfree mice, even though the germ-free mice ingested more food. They also experimented with
transplantation of the gastrointestinal microbiota from conventionally-raised mice into germfree mice. This resulted in the body fat levels of the germ-free mice becoming similar to that
of conventionally-raised mice. These studies prompted more research into the mechanisms
that are employed by the intestinal microbiota to maximize the nutrient availability of
ingested food (Sekirov et al., 2010). Since the conventionally-raised mice were ingesting
fewer calories, yet still gained more weight than the germ-free mice, it is reasonable to infer
that the gastrointestinal microbiota may be degrading certain nutrients into compounds that
can be absorbed and utilized by the host. Many non-digestible carbohydrates including
polysaccharides, oligosaccharides, fiber, and lignin are optimal energy sources for the colonic
microbiota. (Jacobs, et al., 2009) These compounds are broken down into monosaccharides
and short chain fatty acids (SCFA). The major SCFA’s produced as a result of bacterial
fermentation, which mainly takes place in the proximal colon, include acetate, propionate,
and butyrate. Butyrate, in addition to being the major energy source for colonocytes, has been
examined for its effects on human health. Some studies indicate that butyrate may protect
against colon cancer (Hu, et al., 2011, Tang, et al., 2011), intestinal inflammation, and
oxidative stress (Hamer, et al., 2008). Levels of different SCFA’s can be measured in fecal
3

extracts through the use of NMR or gas chromatography (Jacobs, et al., 2009, Murphy et al.,
2010).
Certain bacterial phyla present in the colon are responsible for breaking down
carbohydrates into specific SCFAs. The Firmicutes, which are important starch and fiber
degraders, make up the majority of bacteria present in the colon, and include genera such as
Ruminococcus, Faecalibacterium, Roseburia, Papillibacter, and Clostridium. The main
carbohydrate fermentation products of the Firmicutes include acetate, lactate, formate,
butyrate, and succinate (Jacobs, et al., 2009). Bacteroidetes, which include major genera such
as Bacteroides and Prevotella, are responsible for production of acetate, propionate, and
succinate. Actinobacteria, represented in the colon mainly by Bifidobacterium, produce
lactate, acetate, and formate.

Initial colonization of the human intestinal tract
Prior to birth, the intestinal tract of the human fetus is sterile. While the intestinal
tract is first colonized within hours after birth, the mode of delivery and feeding is important
in determining the types of bacteria that will first colonize the intestinal tract. It is thought
that the early intestinal microbial community could affect future fiber fermentation, short
chain fatty acid metabolism, and vitamin K synthesis (Biasucci). This initial colonization is
also thought to be important in the development of the immune system. Vaginally-delivered
infants are colonized with microorganisms from the mother’s intestinal and vaginal
microbiota, while those delivered by Cesarean section are colonized with microorganisms
from the skin and environment (Biasucci, et al., 2010). Penders, et al., 2006, report that
Cesarean-delivered infants had lower numbers of Bifidobacterium and Bacteroides and were
more likely to be colonized with Clostridium difficile than vaginally-delivered infants. They
also found that infants who were delivered vaginally at home and were breastfed exclusively
4

seemed to harbor the highest numbers of “beneficial” microbes. These infants had the highest
numbers of Bifidobacterium and lowest numbers of E. coli and C. difficile, while formula-fed
infants were more often colonized with E. coli, C. difficile, Bacteroides, and Lactobacillus.
During the first year of life, the composition of the microbial residents of the
gastrointestinal tract is much simpler and less diverse than that of an older child or adult, and
varies widely between individual infants. Both infants and adults are exposed to microbes by
ingesting milk and other foods, however, infants are much more likely to actually be
colonized by these organisms rather than healthy adults with established gastrointestinal
microbial communities (Mackie, et al., 1999). After the first year of life, the intestinal
microbiota becomes more stable and starts to resemble that of children and young adults
(Mackie, et al., 1999). There is also a shift from facultative anaerobes, mainly Enterobacteria,
to strict anaerobes (Hopkins, et al., 2005). As facultative anaerobes colonize the colon, they
consume oxygen, which enables obligate anaerobes, such as Clostridia, Bifidobacteria, and
Bacteroides, to enumerate (Enck et al., 2009). Obligate anaerobic species dominate the colon
in children and adults. Enck et al., 2009 studied fecal samples by conventional culture
techniques from over 12,000 infants and children up to 18 years of age. They found that
Bacteroides spp. and lactobacilli increased with age, while Enterococci and E. coli decreased,
and Bifidobacteria numbers remained stable.

Microbiota in Human Disease
While our intestinal microbiota plays several important roles in human health, as
discussed previously, many recent studies have suggested that deviations in certain types of
bacteria may be linked to several diseases, such as irritable bowel syndrome (IBS) (Matto, et
al., 2005, Maukonen, et al., 2006, Kassinen, et al., 2007, Krogius-Kurrika, et al., 2009, Tana,
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et al., 2010), inflammatory bowel disease (IBD) (Friswell et al., 2010), and possibly even
colon cancer (Sobhani et al., 2011).

Irritable Bowel Syndrome
According to Longstreth et al., 2006, IBS is a common disorder worldwide, with
approximately 10-20% of adults and adolescents affected. It is a functional bowel disorder
that has varied symptoms among those affected, but is associated generally with abdominal
pain, bloating, and changes in bowel habit, but without any visible damage or high-level
inflammation to the large intestine as seen in patients suffering from Crohn’s disease and
ulcerative colitis. Although IBS does not cause as severe of an illness as IBD, it still
significantly affects the quality of life (Salonen, et al., 2010). The Rome III criteria are used
to group IBS-affected individuals into three groups based on stool form and frequency: IBSD (diarrhea-predominant), IBS-C (constipation-predominant), and IBS-M (mixed, or
alternating) (Salonen, et al., 2010, Longstreth, et al., 2006). For a diagnosis of IBS to be
made, pain must be experienced at least 3 days per month over 3 consecutive months, and the
pain must have two of the following three features: (Karantanos, et al., 2010)
1. Relief after defecation
2. Onset of pain associated with change in stool frequency
3. Onset of pain associated with change in stool form
Unfortunately, the actual pathophysiology of IBS is very complex and not yet completely
understood. While deviations in the intestinal microbiota have been noted in studies involving
healthy subjects vs. IBS-affected subjects, other factors are also thought to be involved, such
as visceral hypersensitivity, abnormal gut motility, autonomous nervous system dysfunction,
and psychological factors, such as stress and anxiety (Karantanos, et al., 2010). Low-level
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inflammation of the GI mucosa in IBS patients has also been reported in several studies
(Aerssens, et al., 2008, Chadwick, et al., 2002, Macsharry, et al., 2008).

Irritable Bowel Syndrome and the Intestinal Microbiota
According to Salonen, et al., 2010, there are three main convincing pieces of
evidence that tie the intestinal microbiota to involvement in IBS. The first involves the
correlation between gastrointestinal infections and a particular type of IBS, post-infectious
irritable bowel syndrome (PI-IBS). The gastrointestinal microbiota has also been shown to be
altered in IBS patients in many recently published studies involving subjects with different
subtypes of IBS. In addition, other studies have shown that IBS symptoms can be improved
with treatments that are meant to alter the composition of the intestinal microbiota, such as
probiotics, prebiotics, and antibiotics.

Post-infectious IBS
After a gastrointestinal infection, some patients (7-31%) will go on to develop what
is known as PI-IBS. Most studies of PI-IBS have involved adult patients. While IBS affects
approximately 14% of high school patients and 6% of middle school patients, a study by
Marshall, et al., 2006, reported a high incidence of post-infectious IBS symptoms (36%) in
88 children with positive stool culture results. Microorganisms that are most often associated
with PI-IBS include Salmonella spp., Campylobacter jejuni, and Shigella spp. The length and
severity of the infection are also important factors in the likelihood of developing PI-IBS.
According to Neal, et al., 1997, an illness that lasts longer than 3 weeks has a relative risk of
11.4 compared to an illness lasting less than 1 week. Antibiotic use also increases the risk of
PI-IBS. Maxwell, et al., 2002, state that patients who were given antibiotics were 4 times
more likely than controls to develop bowel problems 4 months after treatment.
7

SIBO (Small Intestinal Bacterial Overgrowth) and IBS
Small intestinal bacterial overgrowth, or SIBO, is a condition that is characterized by
abnormally high numbers of bacteria (>105 organisms/ml) present in the proximal small
intestine, which leads to a competition for nutrients between the host and the bacteria (Rana,
et al., 2008, Scarpellini, et al., 2009). As a result of unusually high bacterial catabolism in
this area of the intestine, toxic metabolites are produced, which can cause injury to the
intestinal enterocytes (Rana, et al., 2008). Symptoms include chronic diarrhea, flatulence,
nausea, and abdominal pain (Rana, et al., 2008). The proper method for SIBO diagnosis has
been debated, but it is generally diagnosed by aspiration and culture of the jejunal contents, or
with lactulose breath testing (Posserud, et al., 2007, Scarpellini, et al., 2009). In a study by
Bouhnik, et al., 1999, jejunal samples from patients with suspected SIBO were cultured, and
bacterial genera recovered included microaerophiles Streptococcus, E. coli, Staphylococcus,
Micrococcus,

Klebsiella, and Proteus, and anaerobes Lactobacillus, Bacteroides,

Clostridium, Veillonella, Fusobacterium, and Peptostreptococcus.
SIBO has been shown to be associated with IBS. In a 2009 study by Scarpellini, et
al., 2009, children with IBS and healthy children were given lactulose breath tests (LBT), and
they found that the LBTs were abnormal in 65% of children with IBS, while only 7% were
abnormal in control children. Several adult studies also suggest a correlation between SIBO
and IBS (Lupascu, et al., 2005, Pimentel, et al., 2003, Carrara, et al., 2008, Majewski, et al.,
2007, Posserud, et al., 2007). Treatment of SIBO usually involves antibiotics. Broadspectrum antibiotics have been effective against Gram negative organisms. Other antibiotics,
such as norfloxacin, amoxicillin, rifaximin, chlortetracycline, and ciprofloxacin were also
used in treatment of SIBO (Rana, et al., 2008). Posserud treated seven SIBO patients with

8

ciprofloxacin, and five showed decreased levels of small-intestinal bacteria after treatment.
Three patients reported an improvement of symptoms after treatment.

Recent Studies of Intestinal Microbiota Among Different IBS Subtypes
While there have been a number of recent studies (Lyra, et al., 2009, Matto, et al.,
2005, Maukonen, et al., 2006, Kassinen, et al., 2007, Krogius-Kurrika, et al., 2009, Tana, et
al., 2010) aimed to determine whether there are significant differences in the intestinal
microbiota between healthy subjects and IBS subjects, the results of these studies do not
show a particular consensus, which may be due to the varying experimental methods used.
Among these methods are conventional culturing, DGGE, qPCR, sequencing, FISH, and
microarray technology, or a combination of these methods. In addition, methods such as
qPCR only allow for study of specifically selected groups of bacteria. The majority use the
Rome II criteria for recruitment of subjects, and all involve adult subjects.

Stability and Variability of IBS Microbiota vs. Healthy Microbiota
A culturing and DGGE-based study by Matto, et al., 2005, suggested that IBS
subjects showed greater temporal instability (changes over time) of their intestinal microbiota
than healthy controls. However, some of the IBS subjects were on antibiotics, which may
explain this finding. A slightly higher number of coliforms and a higher proportion of aerobes
to anaerobes were also reported. A follow-up study by Maukonen, et al., 2006, also studied
temporal stability of the microbiota of IBS vs. healthy subjects by DGGE, and also looked at
the abundance of certain groups of bacteria by affinity capture, a type of quantitative
hybridization-based technique. Similar to the findings by Matto, greater temporal instability
of IBS microbiota as compared to healthy controls was reported. They also saw a decrease in
the proportion of the C. coccoides-E. rectale group in IBS-C subjects compared to healthy
9

controls. In contrast to the previous two studies, a DGGE-based study by Codling, et al.,
2010, reported greater instability and variation in healthy subjects compared to IBS subjects.

Key Differences Observed in the Microbiota of IBS Subtypes
Kassinen, et al., 2007, reported a significantly altered fecal microbiota in IBS. After
16S rRNA library sequencing, they noted decreases in Collinsella aerofaciens, Clostridium
cocleatum, and Coprococcus eutactus in IBS subjects, which were verified by qPCR.
Another 16S rRNA library sequencing and qPCR-based study by Krogius-Kurrika, et al.,
2009, found significant differences between IBS-D subjects and healthy controls. They saw
increases in Proteobacteria and Firmicutes in IBS-D subjects, with a particular increase in the
family Lachnospiraceae within Firmicutes. Decreased Actinobacteria and Bacteroidetes were
also observed compared to healthy controls. A qPCR-based study by Lyra, et al., 2009,
measured levels of 14 different bacterial phylotypes in IBS-D, C, M, and healthy controls.
After multivariate analysis, they reported that the microbiota of IBS-D subjects differed the
most from all other sample groups. Increased Ruminococcus torques and Clostridium
thermosuccinogenes in IBS-D subjects, and increased Ruminococcus bromii in IBS-C
subjects were observed compared to controls. C. thermosuccinogenes was also found to be
increased in IBS-M subjects, while R. torques was decreased as compared to healthy controls.
A second qPCR-based study by Malinen, et al., 2005, examined levels of 20 bacterial
phylotypes. Decreased Lactobacilli were seen in IBS-D subjects compared to IBS-C. An
increase in Veillonella was observed for IBS-C subjects compared to healthy controls.
Overall, in IBS subjects Bifidobacterium catenulatum was decreased, while Ruminococcus
productus and C. coccoides were increased compared to healthy controls. Tana, et al., 2010,
reported higher levels of Veillonella and Lactobacillus in IBS patients compared to controls.
This study also examined levels of SCFA’s, and found that IBS patients had higher levels of
10

acetic, propionic, and total organic acids, which are known to be produced by a combination
of Lactobacillus and Veillonella. Higher levels of acetic and propionic acids also correlated
positively with increasingly worse GI symptoms associated with IBS.

Treatment of IBS
While there is no known cure for IBS at this time, treatments are available that can
help manage symptoms of IBS. The main goal of IBS treatment is to improve symptoms
(abdominal pain, bloating, constipation, diarrhea); thereby improving the quality of life for
the patient. As mentioned previously, SIBO has been treated with antibiotics. Although lowlevel inflammation has been reported in the GI mucosa of IBS patients, (Aerssens, et al.,
2008, Chadwick, et al., 2002, Macsharry, et al., 2008) treatment with anti-inflammatory
drugs such as prednisolone have not been very effective in improvement of IBS symptoms
(Dunlop, et al., 2003). Other drugs, such as smooth muscle relaxants, tricyclic
antidepressants, SSRI’s, and anticonvulsants have been used in treatment of abdominal pain
associated with IBS with some success (Lacy, et al., 2009).
Other treatment options that have been widely used and studied are probiotics and
prebiotics. Probiotics are live bacteria which are administered to the host, usually through a
food product (yogurt, for example) or as a capsule. Generally, they include one or more
members of the genera Bifidobacterium, Lactobacillus, or Streptococcus. Microorganisms
given as probiotics are considered to be beneficial in some way to the host. Once in the host,
some of the bacteria must survive the acidic environment of the stomach and eventually
establish in the colon among the existing colonic microbiota. In order for this to happen, the
bacteria must be administered in large doses over a period of time. Possible health benefits of
probiotics include competitive interactions with pathogenic bacteria, production of
compounds that inhibit the growth of other bacteria, modulation of intestinal inflammatory
11

response, and enhancement of the mucosal barrier function (Quigley, et al., 2010). Prebiotics,
on the other hand, are nondigestible compounds, typically galacto- or fructo-oligosaccharides
that selectively stimulate the growth of certain beneficial bacteria, such as Lactobacillus and
Bifidobacterium (Quigley, et al., 2010).

How do we study the intestinal microbiota?
In order to understand how changes in the composition of the intestinal microbiota
relate to certain disease states (irritable bowel syndrome, inflammatory bowel disease) the
basic composition of the normal, “healthy” microbiota must be determined. The vast majority
of studies use fecal samples or intestinal biopsies as a means of sampling the intestinal
microbiota. Of those studies, fecal samples seem to be used most frequently, mainly due to
the ease and non-invasive nature of collection. In some cases though, fecal samples may not
be ideal. Biopsy specimens may need to be collected for studies focused on the microbiota
associated specifically with the colonic mucosa or the small intestine.
The “classic” method of studying intestinal microbiota involved culturing bacteria
from fecal or biopsy samples onto differential media to select for certain groups, and then
counting the resulting colonies. Culturing was very time-consuming and labor intensive, and
identification of bacteria to the species or strain level was impossible. The majority of gut
microbiota are strict anaerobes, which also makes sample preservation and culturing difficult.
In addition, an estimated 80% of the gut microbiota cannot be cultured due to their unknown
nutritional requirements (Eckburg, et al., 2005). Later, molecular-based methods were put
into practice. Instead of culturing live bacteria from fecal samples, these methods generally
involve extracting DNA or RNA from the bacteria and then amplifying a portion or all of the
16S ribosomal RNA gene for study. This gene is very useful for determining the composition
of complex microbial communities because it has been highly conserved through evolution.
12

The beginning and end of the gene are highly conserved; therefore, universal bacterial
primers can be designed for these regions and the entire 16S rRNA gene can be amplified by
PCR. Primers can also be designed to variable regions of the gene in order to amplify 16S
rRNA sequences for only a certain desired subset of bacteria. Some of the common methods
used recently in studies of intestinal microbiota composition will be briefly discussed in the
following sections.

Molecular Methods Used to Study Intestinal Microbiota
Full-length 16S rRNA sequencing (Sanger sequencing) was used in a study by
Eckburg, et al., 2005, to determine the diversity and composition of the colonic microbiota
from three healthy individuals. Basically, the “pool” of 16S rRNA sequences were compared
and then divided into operational taxonomic units (OTU’s) based on their percent sequence
identity, or similarity. As the number of samples to be analyzed increases, full-length
sequencing can be very costly (Sekirov, et al., 2010). Pyrosequencing is used to amplify
select variable regions of the 16S rRNA gene, and can have 100-fold higher throughput than
Sanger sequencing (Sekirov, et al., 2010). The most significant advantage of sequencing
methods is the ability to detect completely new phylo-species of bacteria. Other methods that
can be used to study the composition of the intestinal microbiota include DGGE (denaturing
gradient gel electrophoresis), TRFLP (terminal restriction fragment length polymorphisms),
FISH (fluorescent in-situ hybridization), and qPCR. For the most part, these methods have
the advantage of being less costly than DNA sequencing, but they cannot give nearly as
“complete” a picture of the intestinal microbiota as a whole as DNA sequencing can. DNA
fingerprinting methods such as DGGE and TRFLP, for example, are based on the ability of
different DNA fragments to be resolved on a gel. However, if a particular phylotype is
present at a low abundance, it is unlikely to be detected by these methods. FISH can be very
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useful under certain circumstances, and low cost is a definite advantage. This method uses
16S rRNA-targeted oligonucleotide probes that are labeled with some type of fluorescent
molecule. These probes can be targeted to large groups of bacteria (phylum or class) or much
more specific groups. Generally though, only a small number of different probes are used
simultaneously for these experiments. qPCR, like FISH, can either be targeted to broad or
very specific groups of bacteria. It is often used as a confirmatory method to FISH
experiments, or vise versa (Sekirov, et al., 2010).

Microarray technology: a new way of studying intestinal microbiota
A more recently introduced, high-throughput method for studying the intestinal
microbiota is the DNA microarray. In a general sense, microarrays contain nucleic acid
probes that are complementary to nucleic acid sequences present in the community of
interest. These probes are affixed at one end to a glass slide or some other surface in a
particular order. Microarray technology in the present day has been applied to many areas of
biological research, such as gene expression in cancer cells, gene upregulation and
downregulation in bacterial and eukaryotic cells under particular conditions, and microbial
community composition studies, to name a few examples. Microarrays used for studying
microbial communities are mainly 16S rDNA based. Early applications of 16S rDNA
microarrays in microbial community analysis were much smaller in scale, containing probes
towards a limited number of specific bacterial species, probes for higher phylogenetic groups
of bacteria, or both (Wang, et al., 2004).
In recent years, several custom 16S rDNA-based microarrays have been developed to
study complex microbial communities, including the HITChip (Human Intestinal Tract Chip),
PhyloChip, and the Microbiota Array that was recently developed in the Paliy laboratory.
(Paliy, et al., 2009, Brodie, et al., 2006, Rajilic-Stovanovic, et al., 2009) The probes on these
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arrays were developed based on bacterial 16S rDNA sequence information, and contained
much higher numbers of probes that aimed to interrogate much larger and more diverse
bacterial populations. The PhyloChip, which was the earliest of these efforts, contains
approximately 500,000 unique probes to bacterial species (Brodie, et al., 2006). The
HITChip, developed by Rajilic-Stovanovic, et al., contains probes to 1140 distinct bacterial
phylo-species, and was validated by interrogating bacterial 16S rDNA from fecal samples
from young adults and elderly adults, and comparing to results obtained by FISH. The
authors also noted the better reproducibility and reliability of results of the microarray
compared to results obtained by DGGE. Paliy, et al., 2009 also recently developed a custom
Microbiota Array designed to interrogate the intestinal microbiota, which contains probes to
775 unique bacterial phylo-species. Validation experiments correctly identified genomic
DNA from 15 different bacterial species. The sensitivity of the microarray was also tested; 30
cycles of 16S PCR dropped the detection limit from 4ng to 10pg of genomic DNA. The
Microbiota Array was also recently employed to demonstrate how the number of PCR cycles
affects bacterial detection and also to examine differences between bacterial presence and
metabolic activity (Rigsbee, et al., 2011). This study also proposed mathematical algorithms
to account for cross-hybridization of 16S rDNA and for the varying numbers of 16S gene
copies in different bacterial groups. After these adjustments were taken into account, results
were more consistent with FISH data (Rigottier-Gois, et al., 2003, Lay, et al., 2005),
suggesting that certain groups of bacteria were previously over-represented and others underrepresented. While these microarrays were all designed to study intestinal microbiota, the
technology could theoretically be applied to study many types of bacterial communities.
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Thesis overview
The work described in this thesis involves a quantitative comparison of the
composition of the intestinal microbiota between healthy adolescents (n=22) and adolescents
diagnosed with irritable bowel syndrome (n=22) through the use of a custom Microbiota
Array, as described and validated by Paliy, et al., 2009. While there have been previous
studies of the intestinal microbiota of adult IBS patients, this study is the first to our
knowledge to present a comprehensive, high-throughput view of the composition of the distal
gut microbiota of healthy and IBS adolescents. In addition, Agans, et al., 2011, recently
showed that the distal gut microbiota of adults is different than that of adolescents. Bacterial
gDNA was isolated from fecal samples. 16S rDNA was amplified by PCR, fragmented, and
loaded onto the microarray. Microarrays were processed in duplicate for each fecal sample.
Microarray results were analyzed as described in Materials and Methods. Microarray data
was validated via qPCR experiments.
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2. MATERIALS AND METHODS

Fecal Sample Collection and Preservation
Fresh fecal samples were collected into sterile containers by healthy adolescent
volunteers (n=22) and newly-diagnosed IBS-D (IBS, diarrhea-predominant) adolescent
volunteers (n=22) as approved by the Wright State IRB committee. For healthy samples, the
age of the donors ranged from 9 to 18 years with a median of 12. For IBS-D samples, the age
of the donors ranged from 8 to 18 years with a median of 13.5. For both sample groups, 10
donors were male and 12 were female. Samples were delivered to Children’s Medical Center,
Dayton, Ohio, and frozen at -80˚C.

Bacterial Genomic DNA Isolation
After homogenization of the fecal samples, bacterial genomic DNA was isolated
from each fecal sample with the ZR Fecal DNA Mini Kit (Zymo Research) by Mr.
Harshavardhan Kenche at Children’s Medical Center. Specifically:

a. 150 mg of homogenized fecal sample and 750 µl of Lysis Solution were added to a
Bashing Bead tube.
b. Tubes were processed in Disruptor Genie for 5 minutes.
c. Tubes were centrifuged at 10,000 g in microcentrifuge for 1 minute.
d. 400 µl of supernatant was transferred to Zymo-Spin IV Spin Filter in a collection
tube and centrifuged for 1 minute at 7000 g.
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e. 1200 µl of Fecal DNA Binding Buffer was added to filtrate and mixed well.
f.

800 µl of mixture from Step 5 was added to Zymo-Spin IIC Column in a collection
tube and centrifuged for 1 minute at 10000 g.

g. Flow through was discarded, and previous step was repeated.
h. 200 µl of DNA Pre-Wash Buffer was added to Zymo-Spin IIC Column in a new
collection tube and centrifuged for 1 minute at 10000 g.
i.

500 µl of DNA Wash Buffer was added to the Zymo-Spin IIC Column in a collection
tube and centrifuged for 1 minute at 10000 g.

j.

The Zymo-Spin IIC Column was transferred to 1.5ml Eppendorf tube. 100ul of
DNase/RNase free water was added to column matrix. Column was centrifuged for
30 seconds at 10000 g.

k. Eluted DNA was transferred to prepared Zymo-Spin HRC-IV spin column and
centrifuged for 1 minute at 8000 g. This column is meant to remove PCR inhibitors
that are typically present in fecal samples.

The concentration of isolated genomic DNA was measured on the Nanodrop 1000
spectrophotometer and an aliquot of each sample was also run on an agarose gel to check
quality. If quality was not sufficient, samples were reisolated.

Amplification and Purification of 16S rDNA
PCR amplification of 16S rDNA was carried out for fecal genomic DNA samples
using

universal

16S-rDNA

specific

(5’AGRGTTYGATYMTGGCTCAG-3’)

bacterial
and

primers

Bact_27F_v4
Univ_1492R

(5’GGYTACCTTGTTACGACTT-3’), with 250ng of starting gDNA in each reaction. 25
cycles of PCR typically produced sufficient product, but occasionally 30 cycles were used.
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Table 2.1: PCR Reaction Mix
Component
Amount
Genomic DNA
250 ng
Bact_27F_v4
1 µl
Univ_1492R
1 µl
Nuclease-free Water Up to 50 µl
Taq 2X Master Mix
25 µl
Table 2.2: Thermocycler Protocol
Step 1
Step 2 (Repeat x25)
Step 3 (Repeat x25)
Step 4 (Repeat x25)
Step 5

95C for 2:00
95C for 0:30
55C for 0:30
72C for 1:30
72C for 10:00

The four PCR reactions for a particular sample were pooled after amplification for
purification with the Qiagen Qiaquick PCR Purification Kit. Specifically:
a. Five volumes of Buffer PB were added to one volume of the PCR reaction,
transferred to a PCR purification column and centrifuged at 17,900 g for 1 minute.
b. The flow-through was discarded and 750 µL of Buffer PE were added to the column,
and column was centrifuged for 1 minute at 17,900 g.
c. Flow-through was discarded, and the column spun down again to ensure removal of
buffer.
d. The spin column was transferred to a new collection tube and 30 µL of RNase free
water, heated to 50˚C, was added to the center of the column and let to sit for 2
minutes
e. The column was centrifuged at 13,000 g for 1 minute to elute amplified DNA.
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The concentration of the purified 16S rDNA was measured on the Nanodrop
spectrophotometer and an aliquot of each sample was also run on an agarose gel to check for
the expected 1.5kbp band.

Fragmentation of 16S rDNA with DNase I
Ideally, 16S rDNA should be in fragments of 100-300bp for hybridization to the
microarray. 1800ng of 16S rDNA was subjected to fragmentation with DNase I (NEB) at a
concentration of 0.04U/µg.

Table 2.3: Fragmentation Reaction
Component
Amount
16S rDNA
1800 ng
DNase I (0.04 U/µl)
1.8 µl
10x DNase Buffer
4 µl
Nuclease-free Water Up to 40 µl
Total Volume
40 µl
Figure 2.1: Polyacrylamide gel showing proper fragmentation

Figure 2.1 shows an ethidium-bromide stained polyacrylamide gel showing an example of
properly fragmented 16S rDNA (left) next to a 100-bp ladder (right).
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Components were mixed well in a 0.5ml Eppendorf tube and placed in the
thermocycler, incubated at 37˚C for 10 minutes, followed by 98˚C for 10 minutes to
inactivate the enzyme. 300ng of fragmented 16S rDNA were combined with water and gel
loading dye and loaded onto a 10% polyacrylamide gel along with a 100-bp DNA ladder to
check for proper fragmentation.

Terminal Labeling with Biotin
The remaining 1500ng of 16S rDNA fragments were end-labeled with biotin. The
reaction was mixed well and incubated at 37˚C for 1 hour in the thermocycler. Reactions
were stopped with the addition of 2µl of 0.5M EDTA.

Table 2.4: Labeling Reaction
Component
Amount
Fragmented 16S rDNA
1500 ng
CoCl2
5 µl
Terminal Transferase (Tdt)
2 µl
10x Tdt Buffer
5 µl
GeneChip Labeling Reagent
2 µl
Nuclease-free Water
2.7 µl
Total Volume
50 µl

Hybridization to Microarray
Hybridization mixtures were prepared and loaded directly into the Microbiota Array.
Microarrays were incubated for 16 hours at 45˚C and 60 rpm in the Affymetrix GeneChip
Hybridization Oven.
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Table 2.5: Hybridization Mixture
Component
Amount
Fragmented, labeled 16S rDNA 1500 ng
2X Hybridization Buffer
65 µl
Control Oligo B2
2.2 µl
100% DMSO
10.2 µl
10 mg/ml Herring Sperm DNA
1.3 µl
50 mg/ml BSA
1.3 µl
Total Volume
130 µl

Washing, Staining, and Scanning of Affymetrix Microarrays
After 16 hours of hybridization, microarrays were removed from the oven. The
hybridization mix was removed from the microarray, frozen at -20˚C and replaced with 160
µl of Wash Buffer A. Staining solutions were prepared according to the Affymetrix protocol.
Washing and staining of the microarrays was carried out on the Affymetrix GeneChip
Fluidics Station 450, using the “Midi_euk_2v3_450” protocol. Scanning of the microarrays
was carried out on the Affymetrix GeneChip Scanner.

Table 2.6: Staining solutions prepared for microarray washing and staining
Streptavidin Vial 1
2x Stain Buffer
50 mg/ml BSA
1 mg/ml Streptavidin
H2O
Total Volume

Amount
300 µL
24 µL
6 µL
270 µL
600 µL

Antibody Soln. Vial 2 Amount
2x MES Stain Buffer
300 µL
50 mg/ml BSA
24 µL
10 mg/ml Goat IgG
6 µL
0.5 mg/ml Anti-strep
6 µL
H2O
270 µL
Total Volume
600 µL
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SAPE Soln. Vial 3
2x MES Stain Buffer
50 mg/ml BSA
1 mg/ml SAPE
H2O
Total Volume

Amount
300 µL
24 µL
6 µL
270 µL
600 µL

Quantitative Real-Time PCR Analysis (qPCR)
Two gDNA samples (one from each sample group) were chosen for qPCR analysis
based on their contrasting microarray results for relative abundance of selected genera. A
standard curve was constructed by combining equal amounts of genomic DNA from each
sample chosen for qPCR analysis. Reactions with five gDNA starting amounts (50pg, 200pg,
1ng, 4ng, 10ng) were run in duplicate for each primer pair. The 27F_v4 primer was used as
the forward primer for all reactions, and reverse primers were either selected from literature
or developed using Ribosomal Database Project (http://rdp.cme.msu.edu/). All qPCR
reactions were carried out on the Abi Prism 7000 (Applied Biosystems) using Perfecta SYBR
Green Supermix (Quanta Biosciences). One genomic DNA sample from each sample group
was chosen based on the contrasting relative abundance values of the genera selected for
qPCR analysis (at least a two-fold difference in relative abundance was desired). Reactions
were run in triplicate with genomic DNA starting amounts of 500ng and 4ng for each primer
pair.
Table 2.7: Reverse primers used for qPCR analysis
Reverse Primer
Eub_338R_3W (universal)
Bifi_162R (Bifidobacterium)
Osci_236R (Papillibacter)
Prev_496R (Prevotella)
Faec_396R (Faecalibacterium)

Sequence (5’→3’)
GCWGCCWCCCGTAGGWGT
CCGGYATTACCACCCGTTT
TCAGACGCGAGGCCATCTTTC
CGGAATTAGCCGGTCCTTAT
CCGAAGACCTTCTTCCTCC
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Source
Amann et al., 1990
Agans et al., (in press)
Agans et al., (in press)
Matsuda et al., 2009
Conte et al., 2006

Data Analysis
Data were initially processed in Affymetrix Gene Chip Operating System (GCOS),
which provides raw signal values and presence/absence calls for probesets. Normalization of
data was carried out with CARMAweb (Rainer) (https://carmaweb.genome.tugraz.at/carma/)
using the MAS5 algorithm for background correction, VSN for normalization, MAS5 for PM
correction, and Median Polish for expression. After normalization, data were inserted into a
custom Microsoft Excel template developed by Dr. Paliy which calculates bacterial
abundances at different phylogenetic levels. It also corrects for cross-hybridization and for
the varying numbers of 16S gene copies in different bacterial genera. 16S copy numbers were
obtained from rrnDB (http://ribosome.mmg.msu.edu/rrndb/index.php) and NCBI Genome
Project (http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi). If the average 16S copy number
for a particular bacterial genus could not be found, higher phylogenetic levels were examined.
Heatmaps were produced with Genesis (http://genome.tugraz.at/) to show the
variation in relative abundance at class and genus levels among individual samples. Principal
Components Analysis of experiments was also performed by importing log2-adjusted signal
values into Genesis. Moderated t-tests with BH adjustment were run using CARMAweb to
determine if there were significant differences at class and genus level between sample
groups.
Core microbiota was assessed by determining the numbers of phylo-species present
in all samples for both groups and for each individual sample. The numbers of shared phylospecies (present in at least two samples) and unique phylo-species (present in only one
sample) were also calculated.
qPCR data was analyzed using a custom Microsoft Excel template. For standard
curves, the log of the DNA starting amount was plotted against Ct values for each primer pair
and a slope was calculated. From the slope values, efficiency values were calculated to allow
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for unequal amplification rates for different primer pairs. For individual qPCR experiments,
average Ct values for each primer pair were assessed against the standard curve using the
Excel template. Relative abundance values of each genus being assessed were calculated with
the template. Ratios of each genus between tested samples were also calculated and compared
to ratios from microarray results.
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3. RESULTS
Overview
Fecal samples were collected from twenty-two healthy adolescents and twenty-two
adolescents suffering from IBS-D. Bacterial gDNA was extracted from each fecal sample and
16S rDNA was amplified via PCR using universal primers as described. 16S rDNA was
fragmented, end labeled with biotin, and hybridized to the Microbiota Array. Microarrays
were washed, stained, and scanned according to Affymetrix protocol. Duplicate microarrays
were processed for each fecal sample with amplified 16S rDNA from separately run PCR
reactions. After analyzing the microarray results in Affymetrix GCOS, raw signal values
were normalized in CARMAweb for both kHLT (healthy adolescent) and kIBS (IBS
adolescent) fecal samples. Normalized signal values and presence/absence calls for all
probesets were copied into the custom Microsoft Excel template to examine the abundance of
bacterial groups at different phylogenetic levels.

Correlation of Replicate Microarrays
Pearson correlations of signal values for duplicate microarrays were automatically
calculated by the custom Microsoft Excel template. On average, the Pearson correlation for
kHLT samples was 0.89±0.05 SD and 0.92±0.03 SD for kIBS samples.
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Comparison of Intestinal Microbiota Abundance at the Class Level
At class level, both kHLT and kIBS groups were dominated by Clostridia, at 72.1%
and 73.5% mean relative abundance, respectively, followed by Actinobacteria, Bacteroidetes,
and Bacilli (Table 3.1). Generally, as mean abundance decreased for a particular class, the
coefficient of variation increased. Clostridia, the most abundant class, had the lowest
variation from one sample to the next. However, the least abundant classes, such as
Alphaproteobacteria, Spirochaetes, and Verrucomicrobiae had much higher variation across
samples. In many cases, these low-abundance classes were not present in every fecal sample.
Pearson correlations of signal values for replicate microarrays were also determined for lowabundance classes only (Alpha, Beta, Gamma, and Deltaproteobacteria, Mollicutes,
Verrucomicrobiae, and Lentisphaerae). For kHLT samples, the average Pearson correlation
for low abundance classes was 0.79±0.08, and 0.86±0.07 for kIBS samples. Since these
values were lower than those calculated for all classes, it may indicate that the high variation
in abundance values for low abundance classes could be due in part to differences in probeset
signal values between replicate microarrays. No significant differences in abundance were
found at class level between kHLT and kIBS samples (p<0.05).
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kHLT Std Error Abundance

kHLT Coeffcient of Variation

kIBS Mean Abundance

kIBS Std Error Abundance

kIBS Coefficient of Variation

Alphaproteobacteria
Betaproteobacteria
Gammaproteobacteria
Deltaproteobacteria
Epsilonproteobacteria
Clostridia
Mollicutes
Bacilli
Actinobacteria
Spirochaetes
Bacteroidetes
Fusobacteria
Verrucomicrobiae
Lentisphaerae

kHLT Mean Abundance

Class

Table 3.1: Comparison of Mean Abundance at Class Level

0.1%
0.7%
0.5%
0.9%
0.0%
72.1%
1.3%
4.3%
10.2%
0.1%
8.5%
0.0%
1.2%
0.2%

0.1%
0.1%
0.1%
0.2%
0.0%
1.1%
0.3%
0.4%
0.9%
0.0%
0.6%
0.0%
0.2%
0.2%

414.7%
92.6%
121.9%
80.3%
7.1%
107.1%
45.3%
43.8%
218.6%
31.5%
92.2%
421.1%

0.0%
0.7%
0.7%
0.6%
0.0%
73.5%
1.2%
4.8%
8.7%
0.0%
8.7%
0.0%
0.8%
0.1%

0.0%
0.1%
0.2%
0.1%
0.0%
1.4%
0.2%
0.4%
1.1%
0.0%
0.7%
0.0%
0.2%
0.1%

91.1%
98.7%
94.0%
9.0%
79.9%
37.0%
61.9%
154.6%
39.7%
127.3%
460.5%

Table 3.1 presents mean abundance, standard deviation, and variation at class level for kHLT
and kIBS samples.

Figure 3.1 presents heatmaps showing the variation in relative abundance of the four
most abundant bacterial classes among individual kHLT and kIBS fecal samples. The upper
maximum (shown in red) was set to 80% relative abundance, and the minimum was set to
zero. This was done to ensure that the variations in relative abundance values for all classes
could be visualized in the heatmap. Class Clostridia ranged from 63.5% to 83.4% relative
abundance in kHLT samples and from 58.9% to 85.1% in kIBS samples, while relative
abundance of Bacteroidetes ranged from 0.0% to 13.2% in kHLT samples, and 2.6% to
16.4% in kIBS samples. Actinobacteria also showed wide variation among individual
samples, with relative abundance of 0.2% to 21.1% in kHLT samples and 0.1% to 17.5% in
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kIBS samples. Actinobacteria are mainly represented in the colon by the genus
Bifidobacterium, which is frequently included in probiotic supplements and yogurts.
Consumption of Bifidobacterium-containing products may help to explain the high variability
of Actinobacteria levels between samples. Bacilli, the fourth most abundant class, ranged
from 1.0% to 7.7% in kHLT samples, and 2.1% to 10.4% in kIBS samples.

Figure 3.1: Relative Abundance at Class Level for kHLT and kIBS samples
A.

B.

Figure 3.1A shows the variation in relative abundance at class level for kHLT samples and
Figure 3.1B shows variation for kIBS samples.

Comparison of Intestinal Microbiota Detection at Class Level
The average number of probesets detected for each class was also assessed for kHLT
and kIBS samples, which refers to the number of bacterial phylo-species called present by the
Microbiota Array. The array contains probesets for 775 different bacterial phylo-species, and
the mean total number of probesets detected was equal for both sample groups at 306, which
29

corresponds to 39% of all probesets being called present for both sample groups. Bacterial
detection varied widely among individual samples in both groups. For kHLT samples, the
number of present probesets ranged from a minimum of 207 (27%) to a maximum of 406
(52%), while kIBS samples showed similar results with a minimum of 215 (28%) to a
maximum of 399 (51%).

Class

kHLT Mean Detection

kHLT Std Error

kHLT Coeffcient of
Variation

kIBS Mean Detection

kIBS Std Error

kIBS Coefficient of
Variation

Table 3.2: Comparison of Mean Probeset Detection at Class Level

Alphaproteobacteria
Betaproteobacteria
Gammaproteobacteria
Deltaproteobacteria
Epsilonproteobacteria
Clostridia
Mollicutes
Bacilli
Actinobacteria
Spirochaetes
Bacteroidetes
Fusobacteria
Verrucomicrobiae
Lentisphaerae
Total

0.3
2.0
2.9
1.2
0.1
247.1
4.5
9.9
10.2
0.6
26.0
0.1
0.7
0.3
306.0

0.1
0.2
0.3
0.2
0.1
10.7
0.3
0.5
0.9
0.2
2.4
0.1
0.1
0.1
13.6

203.1%
55.6%
44.9%
81.1%
257.6%
20.4%
36.1%
24.1%
41.8%
124.1%
43.3%
323.7%
62.7%
149.8%
20.9%

0.3
2.7
4.4
0.7
0.2
241.9
4.7
11.9
11.0
0.8
26.5
0.1
0.6
0.1
306.0

0.1
0.3
0.3
0.2
0.1
9.2
0.3
0.5
1.0
0.2
1.9
0.1
0.1
0.1
11.6

167.1%
48.0%
34.3%
105.5%
188.7%
17.7%
29.0%
20.1%
42.3%
104.2%
34.1%
257.6%
77.4%
257.6%
17.8%

Table 3.2 presents the mean number of present probesets detected for kHLT and kIBS
samples, standard error, and coefficients of variation. The mean total number of probesets
detected was equal for both groups.
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Comparison of Intestinal Microbiota Abundance at Genus Level
While examining the composition of the intestinal microbiota at class level provides
a broad picture of present organisms, examining the composition at lower phylogenetic
levels, such as genus level, provides a more complete picture of the individual
microorganisms that make up the intestinal microbiota across different sample groups, and
may help identify key differences between groups. Although the Microbiota Array can detect
phylo-species from 115 genera, many are either not detected or detected at very low levels.
Genera present at 1.5% relative abundance or higher for at least one sample group are shown
in Table 3.3. Twelve genera listed in Table 3.3 belong to the class Clostridia, which made up
the majority of relative abundance at class level. Ruminococcus was by far the most abundant
genus detected in both kHLT and kIBS samples, with mean abundances of 21.5% and 23.0%,
respectively. Among all genera listed, Ruminococcus also had the lowest coefficient of
variation. Faecalibacterium, the second most abundant genus, was present at 9.1% mean
abundance in kHLT samples and 9.4% in kIBS samples. Bifidobacterium, a member of class
Actinobacteria, was present at 8.4% relative abundance on average in kHLT samples and
6.5% in kIBS samples. Mean relative abundance of Prevotella was 3.5 times higher in kIBS
samples, however; this difference can mainly be attributed to two individual kIBS samples
(kIBS04 and kIBS17) which had over 7% relative abundance of Prevotella. No significant
differences were observed between sample groups (p<0.05).
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Genus

Class

kHLT Mean Ab.

kHLT Std Error Ab.

kIBS Mean Ab.

kIBS Std Error Ab.

Table 3.3: Comparison of Average Abundance of Selected Genera for kHLT and kIBS
samples

Clostridium
Acetivibrio
Anaerotruncus
Dorea
Faecalibacterium
Subdoligranulum
Lachnospira
Anaerostipes
Roseburia
Ruminococcus
Eubacterium
Papillibacter
Streptococcus
Collinsella
Bifidobacterium
Bacteroides
Prevotella

Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Bacilli
Actinobacteria
Actinobacteria
Bacteroidetes
Bacteroidetes

2.8%
2.1%
3.3%
2.1%
9.1%
2.8%
3.3%
2.3%
5.3%
21.5%
4.1%
5.6%
2.8%
1.4%
8.4%
6.0%
0.4%

0.2%
0.2%
0.3%
0.1%
0.6%
0.2%
0.3%
0.1%
0.4%
0.9%
0.2%
0.4%
0.4%
0.3%
0.8%
0.4%
0.2%

2.6%
1.7%
2.7%
2.5%
9.4%
2.7%
3.0%
2.5%
5.9%
23.0%
4.3%
5.9%
3.2%
1.8%
6.5%
5.9%
1.4%

0.2%
0.1%
0.2%
0.2%
0.6%
0.2%
0.2%
0.1%
0.4%
0.9%
0.3%
0.3%
0.3%
0.3%
1.0%
0.6%
0.5%

Table 3.3 shows the average relative abundance and standard error of 17 selected genera for
kHLT and kIBS samples.
Figures 3.2 and 3.3 present scatter plots showing the differences in relative
abundances of bacterial genera between kHLT and kIBS samples. kHLT mean relative
abundance values are plotted on the x-axis, and kIBS mean relative abundance values are
plotted on the y-axis. Error bars represent standard error of the mean (SEM). Figure 3.2
shows that the majority of the data points cluster below 1% relative abundance, which
represent the genera that were either not present or present at very low levels. Also, it was
noted that the vast majority of data points clustered around the diagonal, indicating that mean
relative abundances of most genera did not show much variation on average between healthy
adolescent samples and IBS samples. Figure 3.3 shows the mean relative abundances of
genera present at <2.0% in samples.
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Figure 3.2: Mean Abundance at Genus Level for kHLT and kIBS samples

Figure 3.2 presents a scatter plot of the mean relative abundances of all genera for kHLT and
kIBS samples. Ruminococcus, present at 21.5% abundance in kHLT samples and 23.0%
abundance in kIBS samples, is not shown.
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Figure 3.3: Mean Abundance at Genus Level for kHLT and kIBS samples for Genera
with <2% Relative Abundance

Figure 3.3 presents a scatter plot of the mean relative abundances of genera with <2%
abundance for kHLT and kIBS samples.
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Figure 3.4 shows variation among individual samples in relative abundance values of
the most abundant genera. The upper maximum was set to 25% relative abundance (shown in
red), and the minimum was set to zero (shown in dark blue) Ruminococcus,
Faecalibacterium, Bifidobacterium, and Bacteroides were the most abundant genera among
individual samples. Relative abundance of genus Ruminococcus ranged from 14.2% to 32.9%
in kHLT samples and from 15.5% to 31.9% in kIBS samples. Faecalibacterium ranged from
4.3% to 15.1% in kHLT samples and from 0.0% (kIBS02) to 13.8% in kIBS samples. A
reduction in Faecalibacterium has been associated with IBD in some studies (Friswell, et al.,
2010, Sokol, et al., 2009); therefore, subject kIBS02 may have been incorrectly diagnosed
with IBS rather than IBD. Bifidobacterium also varied widely in relative abundance among
individual samples, and while a somewhat higher mean abundance was seen in kHLT
samples (8.4% vs 6.5%), kIBS samples had more instances in which Bifidobacterium was
either not present or present at very low abundance. In summary, all genera varied widely in
relative abundance among individuals for both kHLT and kIBS samples, and many genera
were not present in every sample.
Figure 3.4: Relative Abundance at Genus Level for kHLT and kIBS samples
A.
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B.

Figure 3.4A shows variation of relative abundances of genera for kHLT samples and Figure
3.4B shows kIBS samples.
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Comparison of Intestinal Microbiota Detection at Genus Level
The mean numbers of detected probesets for selected genera are listed in Table 3.4
for kHLT and kIBS samples. Slight differences in the mean number of probesets detected
were observed between kHLT and kIBS samples.

12.0
8.7
16.4
10.4
13.2
7.5
6.1
5.6
23.5
73.2
10.6
27.3
5.7
0.9
6.4
17.5
1.0

0.5
1.0
1.2
0.4
0.4
0.4
0.2
0.3
0.8
2.0
0.6
2.1
0.3
0.2
0.6
1.3
0.3

12.1
7.0
13.4
9.8
13.6
8.0
5.8
5.5
24.0
72.8
10.3
27.0
6.8
1.1
5.8
18.0
2.2

kIBS Std Error

kIBS Mean Detection

Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Clostridia
Bacilli
Actinobacteria
Actinobacteria
Bacteroidetes
Bacteroidetes

kHLT Std Error

Class

Clostridium
Acetivibrio
Anaerotruncus
Dorea
Faecalibacterium
Subdoligranulum
Lachnospira
Anaerostipes
Roseburia
Ruminococcus
Eubacterium
Papillibacter
Streptococcus
Collinsella
Bifidobacterium
Bacteroides
Prevotella

kHLT Mean Detection

Genus

Table 3.4: Comparison of Mean Probeset Detection at Genus Level

0.6
0.8
1.0
0.6
0.7
0.4
0.3
0.3
1.0
1.6
0.5
2.0
0.2
0.2
0.7
1.1
0.6

Table 3.4 presents mean number of present probesets detected for kHLT and kIBS samples
and standard error.
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Microbiota Core
In addition to examining differences in the intestinal microbiota composition between
healthy children and children with IBS, the “core” microbiota was also investigated. The core
microbiota is essentially bacterial phylo-species that are detected among all samples within a
population. This concept of a core microbiota is important because it can identify and
separate “indisposable” phylo-species that are present in all samples from those that are
detected in only a subset of samples. For example, a phylo-species detected in all 44 samples
analyzed may be more likely to play a significant role in intestinal health and digestion than a
phylo-species detected only sporadically. The number of phylo-species detected in two or
more individual samples (shared phylo-species) and those detected only in one individual
sample (unique phylo-species) were also determined for each sample group. The shared
species represent the “disposable” core, which also may have important roles in digestion and
the breakdown of dietary nutrients, although they are not detected in all samples. Those
species detected in only a single sample may not play a major role in the digestive process
overall, but could possibly be related to the diet of the individual donor. It is also possible that
the core microbiota is closely related to the general tolerance of the immune system of
healthy humans towards particular commensal phylo-species of intestinal microbiota. The
immune systems of individual human subjects may vary with regards to tolerance of different
bacterial species within the GI tract, which may also affect the numbers of shared phylospecies.
Analysis of each sample group individually revealed that there were 56 core phylospecies detected in kHLT samples and 46 core phylo-species detected in kIBS samples
(Figure 3.5). Of these, 34 were detected in every sample for both groups, while 22 phylospecies were detected consistently across all kHLT samples and 12 across all kIBS samples
(Figure 3.6). Figure 3.5 also shows the numbers of phylo-species detected in at least two
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individual kHLT or kIBS samples (shared), and the number of phylo-species present only in
one sample for a group (unique). Figure 3.7 shows the genus composition of the 34 probesets
called present in every sample across both groups. Twenty-five probesets, or 73%, belonged
to Ruminococcus, while three probesets belonged to Roseburia, and two to Streptococcus.
One phylo-species from Clostridium, Lachnospira, Anaerostipes, and Papillibacter
contributed the remaining probesets. Table 3.5 also shows the composition at genus level of
the probesets detected across all samples and for each sample group individually.
Ruminococcus contributed the greatest number of core probesets in all sample groups, while
Faecalibacterium probesets only contributed to the core phylo-species of kHLT samples.
This may be due to the lack of Faecalibacterium in sample kIBS02 (discussed previously).

Figure 3.5: Core, shared, and unique phylo-species detected for each sample group or
individual sample

kIBS

kHLT

Figure 3.5 shows the number of phylo-species detected among all individual samples (core)
for each sample group, the number of phylo-species shared by at least two individual samples
(shared), and the number of unique phylo-species in each sample (unique).
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Figure 3.6: Core phylo-species detected in kHLT and kIBS groups

Figure 3.6 shows the number of phylo-species detected consistently across both sample
groups and across each group individually.
Note: Special thanks go to Richard Agans for creating the illustrations used in Figures 3.5
and 3.6 and for developing the template used for calculation of core phylo-species values.

Figure 3.7: Composition of core phylo-species shared across both sample groups

Figure 3.7 shows the composition of the 34 probesets called present in all kHLT and kIBS
samples.
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kIBS only

kHLT only

kHLT and kIBS

Genus

Table 3.5: Genus composition of core phylo-species

25
6
4
Ruminococcus
5
Faecalibacterium
3
4
1
Roseburia
1
1
1
Papillibacter
2
1
Streptococcus
1
3
1
Clostridium
1
Lachnospira
1
1
Anaerostipes
1
Turicibacter
1
Anaerotruncus
1
Dorea
1
Acetivibrio
1
Bacteroides
1
Subdoligranulum
Total probesets
34
22
12
Table 3.5 presents number of probesets detected for each genus across all samples (kHLT and
kIBS) and across all samples for one sample group (kHLT only or kIBS only).
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Principal Components Analysis
Principle Components Analysis of experiments was carried out using Genesis. The
two sample groups did not separate in PCA space. kHLT samples are shown in blue and kIBS
samples in red (Figure 3.8).

Figure 3.8: Principle Components Analysis

Figure 3.8 shows results of Principle Components Analysis of experiments.

qPCR Validation of Microbiota Array Results
Quantitative real-time PCR was carried out to validate results obtained by
microarray.

Reverse

primers

for

Bifidobacterium,

Papillibacter,

Prevotella,

and

Faecalibacterium were either selected from literature or developed in our lab. These primers
were tested first with qualitative PCR, and agarose gel electrophoresis was carried out to
ensure that binding of the primers occurred only at the intended positions and that the
amplicon sizes were correct. The 27F_v4 universal primer was used as the forward primer.
One sample from each group (kIBS17 and kHLT12) was selected for qPCR analysis based on
contrasting microarray results. qPCR reactions were carried out for 40 cycles. Melting curves
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were also constructed to ensure that binding of primers only occurred in one position. The
results showed that the ratios of relative abundance were in good concordance, although the
ratio of Prevotella was higher for microarray results compared to qPCR results. This may be
due to the highly sensitive and variable nature of qPCR reactions.

Table 3.6: Results of qPCR Validation Experiments
Genus
Microarray Results qPCR results*
0.3
0.1±0.1
Bifidobacterium
0.6
0.4±0.1
Papillibacter
15.6
3.8±0.4
Prevotella
1.0
0.8±0.5
Faecalibacterium
Table 3.6 shows the ratio of relative abundance (kIBS to kHLT) obtained by microarray and
by qPCR. Only the results from the 500pg starting gDNA reactions were used in calculation
of qPCR results.
* Standard error
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4. DISCUSSION
This study aimed to examine differences in the intestinal microbiota between
adolescents newly-diagnosed with IBS-D and healthy adolescents through the use of a
custom Microbiota Array. Although there have been previous publications which investigated
the differences in the intestinal microbiota between healthy adults and those with IBS, there
has been a lack of studies involving adolescent patients. In addition, those studies did not
quantitatively interrogate the entire intestinal microbiome; they only measured levels of
certain selected phylo-species through qPCR and sequencing methods. In contrast, the
utilization of a microarray in this study gave a much more comprehensive picture of the
composition of the intestinal microbiota of healthy and IBS patients.
Twenty-two fecal samples were collected from individuals in each group. Bacterial
gDNA was extracted from each sample and 16S rDNA was amplified with PCR, which was
fragmented, end-labeled with biotin, and hybridized to the Microbiota Array. On average,
306 probesets were detected for each sample group. Much variation in relative abundance
among individual samples was observed at both class and genus levels for healthy and IBS-D
groups. No significant differences in mean relative abundance were seen at class or genus
level, which differs from previous studies involving healthy and IBS adults (Kerckhoffs, et
al., 2009, Lyra, et al., 2009, Matto, et al., 2005, Maukonen, et al., 2006, Kassinen, et al.,
2007, Krogius-Kurrika, et al., 2009, Tana, et al., 2010). Sample groups also failed to separate
in PCA space. Overall, the results suggest that while a few consistencies with previous
studies were seen at genus level, no statistically significant differences were observed
between sample groups. Lower amounts of Bifidobacterium (6.5% vs 8.4%) and higher
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amounts of Veillonella (0.5% vs 0.3%) and Lactobacillus (0.2% vs 0.0%) were observed in
kIBS samples, which are consistent with the findings of Kerckhoffs, et al., 2009 and Tana, et
al., 2010.
There are several possible explanations for these findings. Currently, the exact role of
the intestinal microbiota in IBS is unknown. Some studies indicate that IBS may result from
previous gastrointestinal infection (post-infectious IBS), while others suggest that host
immune response may be an important factor in development of IBS (Quigley, 2011). Several
studies have reported associations between levels of certain bacterial phylo-species and IBS
(Lyra, Matto, Maukonen, Kassinen, Krogius-Kurrika, Tana), however; it cannot be said at
this time whether or not these phylo-species have a role in the actual development or
morbidity of IBS. It is also possible that shifts in the microbiota are seen as a result of the
symptoms of the disease itself after a period of time. Also, while somewhat controversial,
some studies have also suggested that SIBO (small intestinal bacterial overgrowth) may play
a role in the symptoms of IBS (Rana, Scarpellini, Karantanos, Lin, Bouhnik). According to
Lin, et al., 2004, in the healthy individual, easily digestible starches, such as rice, undergo
complete digestion and absorption in the proximal small intestine, and are not available for
fermentation in the distal gut. Fermentation of poorly digestible starches, such as beans, takes
place in the distal gut. However, in SIBO, fermentation of poorly digestible starches takes
place in the ileum, leading to gas production in the small intestine. With more fermentation
occurring in the ileum and fewer nutrients reaching the distal gut, they theorize that the distal
gut bacteria move proximally into the small intestine. If the symptoms of IBS are related to
bacterial overgrowth in the small intestine, it may be unlikely that differences would be
detected in the fecal microbiota between IBS subjects and healthy subjects. In addition, while
a jejunal aspiration and culturing study by Bouhnik, et al., 1999 reported the presence of
Veillonella and Lactobacillus in SIBO patients, many of the genera detected are also found in
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the fecal samples of healthy subjects. In regards to the wide sample-to-sample variation
observed, diet could be an influencing factor. There were no dietary guidelines or restrictions
for the sample donors, except that they were not to have been taking antibiotics within the
previous three months or consuming probiotic supplements. Certain bacterial species, such as
Ruminococcus flavefaciens, are responsible for the enzymatic breakdown of plant cell wall
polysaccharides, while Bacteroides thetaiotamicron is a known starch degrader (Louis). Also,
fructo- and galacto-oligosaccharides have been shown to selectively stimulate the growth of
Bifidobacterium and Lactobacillus species (Louis). Different diets could lead to variations in
the types and amounts of dietary compounds available for microbial breakdown, so it is
plausible that growth of some groups of bacteria may be stimulated or inhibited depending on
their particular nutrient requirements and ability to break down certain dietary compounds.
In addition to the primary breakdown of nutrients, other studies have also shown that
there is metabolic “cross-feeding” between different groups of bacteria. This cross-feeding
could also play an important role in the composition of the intestinal microbiota as it relates
to diet. A recent review by De Vuyst and Leroy discusses the breakdown of inulin-type
fructans (found naturally in bananas, onions, garlic, leeks, and chicory) by the Bifidobacteria,
which results in increased production of lactate, acetate, and butyrate. While Bifidobacteria
can produce lactate and acetate, they do not possess a pathway for butyrate production in
their genomes. However, several other studies have shown that other members of the gut
microbiota can utilize acetate and lactate to produce butyrate. Belenguer, et al., showed that
lactate-utilizing bacteria Eubacterium hallii and Anaerostipes caccae produce butyrate when
grown in a co-culture with Bifidobacterium adolescentis. They also proposed that Roseburia
spp., while not able to utilize lactate, can consume oligosaccharides produced by B.
adolescentis to synthesize butyrate. Another recent study by Chalmers, et al., found that
Streptococcus and Veillonella spp. co-aggregate in dental plaques. Veillonella spp. are non46

saccharolytic; therefore, they are metabolically dependent on other species to provide SCFAs.
In this case, lactic acid produced by Streptococcus is utilized as a carbon source by
Veillonella. While this co-aggregation has not been directly observed in fecal samples, it is
plausible that intestinal species could have a similar metabolic relationship. Unfortunately,
there is insufficient information available about the roles of many of the members of the
distal gut microbiota at lower phylogenetic levels in the breakdown of nutrients, which could
be an interesting area for future work. Greater understanding of the metabolic capabilities of
the intestinal microbiota at low phylogenetic levels and the metabolic relationships between
them, combined with analysis of the diets of the fecal sample donors may shed light on the
variations in the microbiota composition between individuals.
The microbiota core was also determined for both sample groups and for each sample
group individually. Thirty-four bacterial phylo-species were detected consistently across all
fecal samples. Twenty-two phylo-species were detected across all healthy adolescent
samples, and twelve were detected across all IBS adolescent samples. The “shared”
microbiota core, or phylo-species detected among two or more samples for a group, and the
phylo-species detected in only one sample for a group (unique) were also determined.
Analysis of the core microbiota may help to show which species are necessary and
“indisposable” in the distal gut. A phylo-species found to be present across all samples may
play a more important role in the digestive process than a species present in only a subset of
samples. Ruminococcus species comprised 73% of the core microbiota across all samples. As
primary plant cell wall degraders, Ruminococcus species not only made up the majority of the
core microbiota, but also composed the most abundant genus overall at approximately 22%
relative abundance. It also may be important to note that many of the core microbiota genera
were also represented by at least two percent relative abundance.
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Overall, we were able to examine the composition of distal gut microbiota of healthy
adolescents and adolescents suffering from IBS-D and gain a better understanding of the
relationship of the microbiota to disease. In contrast to the findings of several adult studies,
no significant differences were found in microbiota composition at class or genus level
between healthy and IBS fecal samples, but a few consistencies with previous studies were
observed. Future efforts may focus on deeper understanding of the nutritional requirements
and capabilities of lesser known intestinal bacterial genera such as Papillibacter, Roseburia,
Dorea, Anaerotruncus, Lachnospira, and Eubacterium. These genera, while not nearly as
abundant as Ruminococcus and Faecalibacterium, are generally present in most (if not all)
samples, and usually represent at least two percent of the relative abundance. Understanding
the metabolic capabilities of individual genera may also aid in determining the metabolic
relationship of one genus to another. While this study focused on newly-diagnosed IBS-D
patients, it might also be interesting to focus on the changes in microbiota of IBS and healthy
patients over time by collecting fecal samples from the same patients at regular intervals. This
may also help to answer the question of whether IBS is actually caused by some form of
dysbiosis, or if the reported differences between IBS and healthy may be a result of the
disease development itself.
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Appendix A
Additional Publications by the Author
Rigsbee L, Agans R, Foy BD, Paliy O. Optimizing the analysis of human intestinal
microbiota with phylogenetic microarray. FEMS Microbiol Ecol, 2011. 75(2): p. 332-42.
Agans, R, Rigsbee, L, et al, Distal gut microbiota of adolescent children is different from
that of adults. FEMS Microbiology Ecology, 2011. 77(2): p. 404-412.
Rigsbee L, Agans R, et al, Quantitative profiling of the distal gut microbiota of adolescents
with IBS by microbiota array. (submitted)
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